Τίτλος:
Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly fluorouracil and folinic acid chemotherapy in advanced colorectal cancer: A pilot study
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Fifty-two consecutive patients with advanced colorectal cancer who developed persistent diarrhea following chemotherapy with 5-fluorouracil despite dose reduction were treated with amifostine 800, 500 or 150 mg/m 2. The administered dose of 5-fluorouracil was significantly greater during amifostine treatment. Amifostine 800 mg/m2 was associated with complete elimination of diarrhea, but 76.3% of patients developed infusion-related hypotension. At a dose of 500 mg/m2, diarrhea was significantly reduced and milder compared with baseline and the incidence of hypotension was 54.2%. At the lowest dose of amifostine, 17.1% of patients developed Grade 1 diarrhea, a significant reduction over baseline, and hypotension occurred in 25.2% of patients. Treatment with amifostine also improved mucositis but had no effect on the relatively mild nausea and vomiting due to 5-fluorouracil. In this study, amifostine reduced the incidence and severity of diarrhea associated with 5-fluorouracil in patients with advanced colorectal cancer, with acceptable efficacy at a reduced dose that offered better tolerability. © 2003 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
Συγγραφείς:
Tsavaris, N.
Kosmas, C.
Vadiaka, M.
Zonios, D.
Papalambros, E.
Papantoniou, N.
Margaris, H.
Zografos, G.
Rokana, S.
Retalis, G.
Koufos, C.
Περιοδικό:
Journal of Pain and Symptom Management
Εκδότης:
ELSEVIER SCIENCE INC 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
Λέξεις-κλειδιά:
amifostine; antidiarrheal agent; diphenoxylate; fluorouracil; folinate calcium; loperamide; octreotide, adult; advanced cancer; aged; anorexia; article; blood toxicity; bone marrow toxicity; cancer combination chemotherapy; chemotherapy induced emesis; clinical trial; colorectal cancer; controlled clinical trial; controlled study; diarrhea; disease severity; dose response; drug effect; drug efficacy; drug safety; drug tolerability; female; human; hypotension; incidence; low drug dose; major clinical study; male; mucosa inflammation; nausea; pilot study; prophylaxis; treatment outcome
DOI:
10.1016/S0885-3924(03)00283-5
